307 related articles for article (PubMed ID: 27349377)
21. Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption.
Guan J; Jin L; Liu Q; Xu H; Wu H; Zhang X; Mao S
Eur J Pharm Sci; 2019 Nov; 139():105043. PubMed ID: 31415903
[TBL] [Abstract][Full Text] [Related]
22. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
[TBL] [Abstract][Full Text] [Related]
23. Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus®.
Liu J; Zou M; Piao H; Liu Y; Tang B; Gao Y; Ma N; Cheng G
Molecules; 2015 Jun; 20(6):11345-56. PubMed ID: 26102068
[TBL] [Abstract][Full Text] [Related]
24. An investigation of nifedipine miscibility in solid dispersions using Raman spectroscopy.
Keratichewanun S; Yoshihashi Y; Sutanthavibul N; Terada K; Chatchawalsaisin J
Pharm Res; 2015 Jul; 32(7):2458-73. PubMed ID: 25673042
[TBL] [Abstract][Full Text] [Related]
25. Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability.
Liu P; Zhou JY; Chang JH; Liu XG; Xue HF; Wang RX; Li ZS; Li CS; Wang J; Liu CZ
Drug Des Devel Ther; 2020; 14():2959-2975. PubMed ID: 32801637
[TBL] [Abstract][Full Text] [Related]
26. Amorphous Salts Solid Dispersions of Celecoxib: Enhanced Biopharmaceutical Performance and Physical Stability.
Mukesh S; Joshi P; Bansal AK; Kashyap MC; Mandal SK; Sathe V; Sangamwar AT
Mol Pharm; 2021 Jun; 18(6):2334-2348. PubMed ID: 34003656
[TBL] [Abstract][Full Text] [Related]
27. Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery.
Pozzoli M; Traini D; Young PM; Sukkar MB; Sonvico F
Drug Dev Ind Pharm; 2017 Sep; 43(9):1510-1518. PubMed ID: 28425305
[TBL] [Abstract][Full Text] [Related]
28. Investigation of the in vitro performance difference of drug-Soluplus® and drug-PEG 6000 dispersions when prepared using spray drying or lyophilization.
Altamimi MA; Neau SH
Saudi Pharm J; 2017 Mar; 25(3):419-439. PubMed ID: 28344498
[TBL] [Abstract][Full Text] [Related]
29. Comparison of electrospun and extruded Soluplus®-based solid dosage forms of improved dissolution.
Nagy ZK; Balogh A; Vajna B; Farkas A; Patyi G; Kramarics A; Marosi G
J Pharm Sci; 2012 Jan; 101(1):322-32. PubMed ID: 21918982
[TBL] [Abstract][Full Text] [Related]
30. Conjugation of Hot-Melt Extrusion with High-Pressure Homogenization: a Novel Method of Continuously Preparing Nanocrystal Solid Dispersions.
Ye X; Patil H; Feng X; Tiwari RV; Lu J; Gryczke A; Kolter K; Langley N; Majumdar S; Neupane D; Mishra SR; Repka MA
AAPS PharmSciTech; 2016 Feb; 17(1):78-88. PubMed ID: 26283197
[TBL] [Abstract][Full Text] [Related]
31. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
Chavan RB; Lodagekar A; Yadav B; Shastri NR
Drug Deliv Transl Res; 2020 Aug; 10(4):903-918. PubMed ID: 32378174
[TBL] [Abstract][Full Text] [Related]
32. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of spray-dried and freeze-dried hydrocortisone/polyvinyl pyrrolidone solid dispersions.
Dontireddy R; Crean AM
Drug Dev Ind Pharm; 2011 Oct; 37(10):1141-9. PubMed ID: 21615280
[TBL] [Abstract][Full Text] [Related]
34. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers.
Sun DD; Lee PI
J Control Release; 2015 Aug; 211():85-93. PubMed ID: 26054795
[TBL] [Abstract][Full Text] [Related]
35. Kollidon® VA 64 and Soluplus® as modern polymeric carriers for amorphous solid dispersions.
Strojewski D; Krupa A
Polim Med; 2022; 52(1):19-29. PubMed ID: 35766434
[TBL] [Abstract][Full Text] [Related]
36. Effect of preparation method on the surface properties and UV imaging of indomethacin solid dispersions.
Asare-Addo K; Alshafiee M; Walton K; Ward A; Totea AM; Taheri S; Mawla N; Adebisi AO; Elawad S; Diza C; Timmins P; Conway BR
Eur J Pharm Biopharm; 2019 Apr; 137():148-163. PubMed ID: 30836178
[TBL] [Abstract][Full Text] [Related]
37. Study the influence of formulation process parameters on solubility and dissolution enhancement of efavirenz solid solutions prepared by hot-melt extrusion: a QbD methodology.
Pawar J; Suryawanshi D; Moravkar K; Aware R; Shetty V; Maniruzzaman M; Amin P
Drug Deliv Transl Res; 2018 Dec; 8(6):1644-1657. PubMed ID: 29426975
[TBL] [Abstract][Full Text] [Related]
38. Formulation design and evaluation of amorphous ABT-102 nanoparticles.
Jog R; Kumar S; Shen J; Jugade N; Tan DC; Gokhale R; Burgess DJ
Int J Pharm; 2016 Feb; 498(1-2):153-69. PubMed ID: 26705150
[TBL] [Abstract][Full Text] [Related]
39. Solid-state, triboelectrostatic and dissolution characteristics of spray-dried piroxicam-glucosamine solid dispersions.
Adebisi AO; Kaialy W; Hussain T; Al-Hamidi H; Nokhodchi A; Conway BR; Asare-Addo K
Colloids Surf B Biointerfaces; 2016 Oct; 146():841-51. PubMed ID: 27451373
[TBL] [Abstract][Full Text] [Related]
40. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
Patel GV; Patel VB; Pathak A; Rajput SJ
Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
